Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

MRUS
Merus N.V. Common Shares
stock NASDAQ

At Close
Jul 3, 2025 12:59:50 PM EDT
53.81USD+0.900%(+0.48)222,443
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 1, 2025 8:11:30 AM EDT
52.60USD-1.369%(-0.73)0
After-hours
Jul 2, 2025 4:00:30 PM EDT
53.33USD-0.075%(-0.04)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
07:07AM EST  Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus   Benzinga
Jan 25, 2022
04:36PM EST  Merus Appoints Shannon Campbell As Chief Commercial Officer And Regains Worldwide Rights To MCLA-145   Benzinga
04:30PM EST  Merus Appoints Shannon Campbell as Chief Commercial Officer and   GlobeNewswire Inc
Dec 10, 2021
08:04AM EST  Merus Presents Updated Analysis Of Zenocutuzumab, Trastuzumab, And Vinorelbine In Patients With HER2+ Metastatic Breast Cancer At San Antonio Breast Cancer Symposium   Benzinga
08:00AM EST  - The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met   GlobeNewswire Inc
Dec 6, 2021
06:44AM EST  Merus Presents Clinical Data On MCLA-145 At The ESMO Immuno-Oncology Congress 2021   Benzinga
06:43AM EST  Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today released clinical data on MCLA-145 from the phase 1 trial in patients with solid tumors at the ESMO Immuno-Oncology Congress 2021 being held virtually.   GlobeNewswire Inc
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Dec 2, 2021
08:09AM EST  Merus Announces Poster Presentation On Clinical Data On MCLA-145 At ESMO Immuno-Oncology Congress 2021   Benzinga
08:00AM EST  Merus Announces Poster Presentation on Clinical Data on MCLA-145   GlobeNewswire Inc
Nov 12, 2021
06:13AM EST  HC Wainwright & Co. Maintains Buy on Merus, Raises Price Target to $45   Benzinga
Nov 10, 2021
08:00AM EST  Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual).   GlobeNewswire Inc
Nov 5, 2021
09:43AM EDT  The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill   Benzinga
09:31AM EDT  Merus N.V. Announces Common Stock Offering; Size Not Disclosed   Benzinga
09:31AM EDT  Merus Announces Proposed Public Offering Of Common Shares   Benzinga
Nov 3, 2021
09:21AM EDT  RBC Capital Maintains Sector Perform on Merus, Raises Price Target to $33   Benzinga
Nov 2, 2021
05:17PM EDT  Merus Q3 EPS $(0.39) Up From $(0.64) YoY, Sales $6.75M Down From $8.57M YoY   Benzinga
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 8, 2021
04:39AM EDT  SVB Leerink Maintains Outperform on Merus, Raises Price Target to $45   Benzinga
Oct 7, 2021
03:12PM EDT  Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher   Benzinga
12:28PM EDT  Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide   Benzinga
10:44AM EDT  Mid-Morning Market Update: Markets Open Higher; Conagra Brands Profit Beats Views   Benzinga
09:00AM EDT  -- Tumor shrinkage and partial responses observed in patients with advanced head and neck squamous cell carcinoma (HNSCC) treated with MCLA-158 -- In preclinical studies, Zeno observed to block cell growth 100 fold more potently than anti-HER3 antibody alone   GlobeNewswire Inc
Sep 30, 2021
04:36PM EDT  Merus Announces Poster Presentations On Zenocutuzumab And MCLA-158 At The AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics   Benzinga
04:35PM EDT  Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158   GlobeNewswire Inc
Sep 7, 2021
08:00AM EDT  Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in the following investor conferences:   GlobeNewswire Inc
Aug 5, 2021
06:16PM EDT  Merus Q2 EPS $(0.71) Down From $(0.54) YoY, Sales $12.38M Up From $6.06M YoY   Benzinga
Jul 21, 2021
08:07AM EDT  Merus Highlights Publication In Nature Communications On MCLA-145's Novel Mechanism Of Action Promoting Tumor Immunity And Context Dependent T-Cell Costimulation   Benzinga
08:00AM EDT  Merus Announces Publication in Nature Communications on   GlobeNewswire Inc
Jul 7, 2021
04:20PM EDT  Merus to Participate in William Blair's Biotech Focus Conference 2021   GlobeNewswire Inc
Jun 7, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2021   Benzinga
07:48AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:50AM EDT  Citigroup Upgrades Merus to Buy, Raises Price Target to $31   Benzinga
Jun 4, 2021
12:01PM EDT  Merus Presents Clinical Data On Zenocutuzumab In NRG1-fusion (NRG1+) Cancers At 2021 ASCO Meeting   Benzinga
12:00PM EDT  Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion   GlobeNewswire Inc
May 26, 2021
04:01PM EDT  Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 9:00 a.m. ET.   GlobeNewswire Inc
May 19, 2021
05:25PM EDT  Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021   Benzinga
05:01PM EDT  Merus Announces Publication of Abstract on Zenocutuzumab in   GlobeNewswire Inc
May 13, 2021
08:02AM EDT  Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial   Benzinga
08:00AM EDT  Merus Announces Collaborations in Israel, Italy and Spain to   GlobeNewswire Inc
May 11, 2021
08:00AM EDT  Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18 at 8:00 a.m. ET.   GlobeNewswire Inc
May 7, 2021
04:10PM EDT  Merus Filing Shows Registration For $125M Mixed Securities Shelf Offering   Benzinga
May 6, 2021
05:55PM EDT  Merus Q1 EPS $(0.28) Up From $(0.68) YoY, Sales $8.35M Up From $6.30M YoY   Benzinga
May 3, 2021
04:02PM EDT  Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors   Benzinga
04:01PM EDT  Merus Announces First Patient Treated in Phase 1/2 Clinical Trial   GlobeNewswire Inc
Apr 28, 2021
04:01PM EDT  Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the companys selection for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021.   GlobeNewswire Inc
Apr 8, 2021
10:52AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2021   Benzinga
07:09AM EDT  William Blair Initiates Coverage On Merus with Outperform Rating   Benzinga
Mar 19, 2021
05:35AM EDT  Merus N.V. 10% Owner Mark Lampert Reported Purchase of 250,000 Shares @ Avg Price of $23.00/Share in Form 4 Filing on Thurday   Benzinga
Mar 17, 2021
07:54AM EDT  RBC Capital Maintains Sector Perform on Merus, Raises Price Target to $21   Benzinga
07:42AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
06:38AM EDT  HC Wainwright & Co. Maintains Buy on Merus, Raises Price Target to $30   Benzinga
Mar 16, 2021
05:14PM EDT  Merus Q4 2020 EPS $(2.92) Vs $(2.28) YoY   Benzinga
04:58PM EDT  Clinical data and program update planned for lead program zenocutuzumab (Zeno) in 2Q 2021   GlobeNewswire Inc
10:38AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2021   Benzinga
06:58AM EDT  SVB Leerink Initiates Coverage On Merus with Outperform Rating, Announces Price Target of $33   Benzinga
Mar 10, 2021
04:45PM EST  Merus Announces Poster Presentations for Zenocutuzumab and   GlobeNewswire Inc
Mar 8, 2021
08:46AM EST  Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside chat at the 33rd Annual Roth Conference on Monday, March 15 at 2:00 p.m. ET.   GlobeNewswire Inc
Feb 1, 2021
08:00AM EST  Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in the following investor conferences:   GlobeNewswire Inc
Jan 27, 2021
07:36AM EST  The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement   Benzinga
Jan 23, 2021
09:14AM EST  The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More   Benzinga
Jan 22, 2021
07:22AM EST  The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa   Benzinga
Jan 21, 2021
08:43AM EST  Merus Prices 4,848,485 Share Offering At $24.75/Share   Benzinga
08:41AM EST  Merus Announces Pricing of Public Offering of Common Shares   GlobeNewswire Inc
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
10:09AM EST  Merus shares were trading lower after the company announced a $60 million common stock offering.   Benzinga
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 19, 2021
04:18PM EST  Merus Reports $60M Common Stock Offering   Benzinga
04:18PM EST  Merus N.V. Announces Proposed Public Offering of Common Shares   GlobeNewswire Inc
06:48AM EST  Eli Lilly and Co. (LLY), and Merus N.V. (MRUS) have collaborated to discover novel T-cell re-directing bispecific antibodies. As per the collaboration, Merus is eligible to receive for a total of up to about $1.6 billion, Lilly said in a statement.   RTTNews
06:32AM EST  Lilly And Merus NV Announce Collaboration To Discover Novel T-Cell Re-Directing Bispecific Antibodies; Merus To Receive $40M Upfront Cash Payment And $20M equity Investment, Co. Eligible for $540M In Milestones For Up To $1.6B For Three Products   Benzinga
06:31AM EST  Lilly, Merus NV Collaborate To Discover Novel T-Cell Re-Directing Bispecific Antibody Therapies   RTTNews
06:30AM EST  Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing   PR Newswire
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 13, 2021
07:25AM EST  The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations   Benzinga
Jan 12, 2021
04:02PM EST  Merus Announces Collaborations With Nationwide Medical Organizations In The Netherlands And Japan To Enhance Screening And Identification Of Cancer Patients With NRG1 Fusion Tumors And To Raise Awareness Of The eNRGy Clinical Trial   Benzinga
04:01PM EST  Merus Announces Collaborations with Nationwide Medical   GlobeNewswire Inc
Jan 11, 2021
05:14PM EST  SKB Finalizes New Lease Agreement With Twist Bioscience Corporation At Recently Reposition Mixed-Use Campus, ParkWorks Industrial Center   Benzinga
05:11PM EST  Merus Announces Presentation Of Phase 1 Clinical Data For MCLA-158 At American Society Of Clinical Oncology 2021 Gastrointestinal Cancer Symposium   Benzinga
05:10PM EST  Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158   GlobeNewswire Inc
Jan 8, 2021
02:51PM EST  Mid-Afternoon Market Update: Gold Dips 3.5%; Merus Shares Surge   Benzinga
07:25AM EST  The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs   Benzinga
Jan 7, 2021
04:10PM EST  Merus Granted FDA Fast Track Designation of Zenocutuzumab For Treatment Of Patients With Neuregulin 1 Fusion Cancers   Benzinga
04:05PM EST  Merus Granted FDA Fast Track Designation of Zenocutuzumab for the   GlobeNewswire Inc
Dec 28, 2020
04:12PM EST  Merus 13D Shows 11% Active Stake From Incyte Corporation   Benzinga
Dec 26, 2020
09:16AM EST  The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks   Benzinga
Dec 17, 2020
08:12AM EST  Merus And Sema4 Enter Agreement To Support Phase 1/2 Clinical Trial Of Zenocutuzumab   RTTNews
08:02AM EST  Merus and Sema4 Enter Into an Agreement to Support Merus' Phase 1/2 Clinical Trial of Zenocutuzumab   Benzinga
08:00AM EST  Merus and Sema4 Enter Into an Agreement to   GlobeNewswire Inc
Nov 16, 2020
08:00AM EST  Merus N.V.(Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonicsand Triclonics), today announced thatBill Lundberg, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference onTuesday, November 17, 2020at14:40 p.m. GMT/9:40 a.m. ET.   GlobeNewswire Inc
Nov 9, 2020
08:13AM EST  Merus Announces Poster Presentations On MCLA-145 At Society For Immunotherapy Of Cancer   Benzinga
08:00AM EST  Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that preclinical data from its MCLA-145 program will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting being held virtually on November 1015, 2020.   GlobeNewswire Inc
Nov 5, 2020
05:45PM EST  Merus Earlier Reported Q3 EPS $(0.64) Down From $(0.55) YoY, Sales $8.57M Up From $8.15M YoY   Benzinga
Oct 12, 2020
05:07PM EDT  Marus, myTomorrows Announce Expansion Of Collaboration For Screening, eNRGy Clinical Trial Awareness For Cancer Patients With Neuregulin 1 Fusion Tumors   Benzinga
05:00PM EDT  myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the expansion of their ongoing collaboration to raise awareness of screening opportunities for and recruitment of patients with neuregulin 1 (NRG1) fusion cancers.   GlobeNewswire Inc
Aug 7, 2020
08:30AM EDT  Merus N.V.(Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will present a company overview at the 2020Wedbush PacGrow Healthcare ConferenceonWednesday, August 12, 2020at10:20 a.m. ET.   GlobeNewswire Inc
06:30AM EDT  Merus Filing Shows Registration For $75M Common Stock Offering   Benzinga
Aug 6, 2020
04:47PM EDT  Merus Q2 EPS $(0.54) Down From $(0.52) YoY, Sales $6.06M Down From $6.19M YoY   Benzinga
Jul 27, 2020
08:25AM EDT  Merus Announces FDA Orphan Drug Designation Of Zenocutuzumab For Treatment Of Pancreatic Cancer   RTTNews
08:24AM EDT  Merus Names Andrew Joe Chief Medical Officer   RTTNews
08:01AM EDT  Merus Announces FDA Orphan Drug Designation Of Zenocutuzumab For The Treatment Of Pancreatic Cancer   Benzinga
08:01AM EDT  Merus Appoints Andrew Joe, M.D., as Chief Medical Officer   GlobeNewswire Inc
08:00AM EDT  Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Zenocutuzumab (Zeno) for the treatment of patients with pancreatic cancer.   GlobeNewswire Inc
Jul 13, 2020
04:02PM EDT  Merus Reports Collaboration With Caris Life Sciences To Detect NRG1 Fusions In Cancer Patients   Benzinga
04:01PM EDT  Caris to provide DNA and RNA molecular testing to supportpatient identification and enrollment for Merus Zenocutuzumab Phase 1/2 eNRGy trial   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC